Real world use of lanreotide in neuroendocrine tumors.

ABSTRACT:

Background

Treatment for metastatic neuroendocrine tumors (NETs) is often with somatostatin analogues (SSA) such as lanreotide in the first-line setting. Real world use of lanreotide in Canada is not well studied.

Methods

We performed a retrospective chart review of 69 patients to study real world use of lanreotide at our centre.

Results

Lanreotide was the first-line of systemic treatment in 60 patients. Watch-and-wait was a common strategy and was seen in 31 patients. SSA switch strategy was seldom applied. Majority of patients on lanreotide had low-grade NETs. Standard starting dose of lanreotide 120 mg every 28 days was used in 66 patients. Dose escalation to 120 mg every 21 days occurred in 7 patients. The primary intention for treatment was tumor control in 32 pa

SUBMITTER: Siddiqui Z 

PROVIDER: S-EPMC10331746 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature